Trump administration announces funding for PTSD research on ibogaineWIRED investigation examines Jensen Huang's comments on defining women's power in techWalmart launches early Black Friday promotions on select giftsMint Mobile offers $500 discount on select new phones for new customers signing up for a yearRussia and Iran criticize U.S. Caspian task force amid reports of joint sanction evasion effortsNewly elected US lawmakers pose for traditional group photo at Capitol ahead of 120th Congress openingUS existing home sales drop to lowest monthly level in yearsPro-Palestine philanthropist faces US extradition hearing in SpainLewisham Islamic Centre criticizes charity watchdog over warning on Palestine commentsSenegalese wrestlers succeed in beach wrestling at Dakar Youth OlympicsUS nonprofits file lawsuit seeking pause on advanced AI model trainingDemocrats convene in Denver to discuss party direction after midterm victoriesUS releases report on $12bn from Venezuelan oil, mineral resourcesPope Leo XIV urges Catholic Church to address clergy sexual abuseShooting near White House results in death, suspect later found dead
All fact checks
AI analysis

Fact check

“The FDA’s filing review phase typically takes longer than the acceptance review.”
UnverifiableConfidence: LOW

Reasoning

The provided evidence includes statements that the acceptance phase can exceed statutory deadlines and that the subsequent filing review "typically takes even longer than 'acceptance' review," directly supporting the claim that the filing review phase is usually longer.

On confidence: Two independent excerpts from the same Reason.com article explicitly state that the filing review phase typically takes longer than the acceptance review.

Important context

The evidence pertains to FDA review timelines for nicotine product applications under the 2021 Final Rule, citing specific case examples and plaintiff arguments.

Evidence

Supporting (2)

Limitations

Both excerpts come from a single secondary reporting source; no primary FDA documentation is provided to corroborate the typical duration across all product categories. No independent origin corroborated this claim, so it cannot be verified and confidence cannot be high.

Last verified:
Oct 1, 2026, 4:41 AM CDT
Pipeline:
2.1.0
Claim type:
Factual

Where this claim appeared

The FDA Promises To Streamline the Dauntingly Complex Rules for Approving Nicotine Products

Reason · Jacob Sullum